Iodine-131 sodium iodide solution (for preparation of oral solution or capsules)

Approved Use: Treatment of hyperthyroidism and thyroid carcinomas that take up iodine

---

Brand Name: HICON®
Manufacturer: Jubilant DraxImage
Package Insert
How Supplied: 

• 250 mCi
• 500 mCi
• 1000 mCi

Concentration: 1000 mCi/mL
Calibration:

• Sunday 12:00 ET
• Monday 12:00 ET
• Saturday 12:00 ET

Expiration:

• 9 days after calibration date (14 days after manufacture date)
• Compounded capsule expires 7 days after preparation date
• *Solution expiry versus compounded capsule expiry*

Availability: See chart below.  Earliest delivery arrives 4 days pre-cal
Gelatin Capsule Blister Pack:

• Contains 10 (size #2) inner gel caps containing ~300mg dibasic sodium phosphate anhydrous USP  
• Contains 10 (size #1) empty gelatin capsules
• Discard unused capsules after all HICON® has been dispensed

NDC #: 
65174-880-25
65174-880-50
65174-880-00
​
Kit Information
Old Formulation vs. New Formulation
​Letter from Manufacturer August 2016 (appropriate use of blister packs)
Letter from Manufacturer February 2012 (new formulation - launch date)
Letter from Manufacturer December 2011 (new formulation approved)

HICON® Availability Chart:

Ship Day	Delivery Day	Calibration Day
Monday	Tuesday	Saturday
Tuesday	Wednesday	Sunday
Wednesday	Thursday	Monday

---

​Manufacturer: Curium (DISCONTINUED 2018) 

---

Clinical Guidelines:

• ATA Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer (2015)
• ATA Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer (2015)
• ​ACR Practice Parameter for the Performance of Therapy with Unsealed Radiopharmaceutical Sources (2015)
• ACR-SPR Practice Parameter for the Performance of Scintigraphy and Uptake Measurements for Benign and Malignant Thyroid Disease (2014)
• ​SNMMI Procedure Standard for Therapy of Thyroid Disease with Iodine-131 (Sodium Iodide) 3.0 (2012)
• ​Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists (2011)
• ​Radiation Safety in the Treatment of Patients with Thyroid Diseases by Radioiodine I-131: Practice Recommendations of the American Thyroid Association (2011)
• ACR-SNMMI-SPR Practice Guideline for the Performance of Thyroid Scintigraphy and Uptake Measurements (2009)
• EANM Procedure Guidelines for Therapy of Benign Thyroid Disease (2010)
• EANM Guidelines for Radioiodine Therapy of Differentiated Thyroid Cancer (2008)
• SNMMI Procedure Standard Scintigraphy for Differentiated Papillary and Follicular Thyroid Cancer (2006)
• SNMMI Procedure Standard for Thyroid Scintigraphy 3.0 (2006)
• SNMMI Procedure Standard for Thyroid Uptake Measurement 3.0 (2006)

Patient Information:

• NRC: Information for Patients Administered Radioactive Iodine (I-131)​

Allergy Information:

• Radioiodine Treatment Despite History of 'Iodine Allergy'